CGEM

Cullinan TherapeuticsA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

Probability

Target price

$26.00

+70.9% vs current

Most likely

Base case

Probability

Target price

$18.00

+18.3% vs current

B-

Bear case

Probability

Target price

$9.00

-40.8% vs current

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Sentiment is moderately positive but still monitoring-oriented: the deterministic prior leans positive, primary-source support is solid, and 2026 has real dated catalysts, yet the setup remains low-conviction because value creation still hinges on multiple early-to-mid-stage clinical events rather than established commercial traction.

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30eventCLN-978 initial SLE and RA data in Q2 2026High impact

Management guided to initial OUTRACE SLE and RA data in Q2 2026, focused on safety, B-cell depletion, biomarkers, and preliminary clinical activity; this is the cleanest near-term proof point for Cullinan's autoimmune T-cell engager thesis [#10-K-2026-03-10] [#8-K-2026-03-10].

2026-09-30eventCLN-049 expansion and data updates through 2026High impact

Cullinan expects to start CLN-049 monotherapy dose-expansion cohorts in Q2 2026, provide a dose-escalation update in H2 2026, and finish expansion enrollment in Q4 2026 to inform an RP2D for a planned registrational path; positive AML signal quality would materially improve the oncology leg of the story [#10-K-2026-03-10] [#8-K-2026-03-10].

2026-12-31eventZipalertinib regulatory and Phase 3 progressHigh impact

Taiho completed the rolling NDA submission for zipalertinib in February 2026, completed REZILIENT3 enrollment, and expects top-line Phase 3 results by year-end 2026; Cullinan is eligible for $30 million on second-line U.S. approval, up to $100 million on first-line U.S. approval, and a 50/50 U.S. profit share, so de-risking here matters beyond sentiment [#10-K-2026-03-10] [#8-K-2026-03-10].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology